top stories

Con­tract re­search is hav­ing a mo­ment right now. Will M&A splash­es dri­ve the in­dus­try to even greater heights?

11 hours ago
R&D
In Focus

Mer­ck emerges as lead bid­der in po­ten­tial Ac­celeron buy­out with deal pos­si­ble this week — re­port

Yesterday
Deals
Pharma

Safe­ty fears force Pfiz­er to change piv­otal DMD gene ther­a­py tri­al pro­to­col

11 hours ago
R&D
Cell/Gene Tx

As sup­ply chain wor­ries ease up, Big Phar­ma CEOs have a new top con­cern: re­cruit­ing and keep­ing em­ploy­ees

11 hours ago
People
Pharma

Latest

Most read

Days of heat­ed ru­mors cul­mi­nate in a re­port that Ac­celeron is in ad­vanced buy­out talks

4 days ago
Deals
R&D

NIH spot­lights trio of aca­d­e­m­ic teams chas­ing af­ter 'pan-coro­n­avirus' vac­cines

11 hours ago
Discovery

French biotech and Pfiz­er find pos­i­tives in da­ta for Ly­me dis­ease vac­cine can­di­date; Al­tim­mune's obe­si­ty drug shows ...

12 hours ago
News Briefing

Zio­pharm lays off half its staff af­ter man­u­fac­tur­ing is­sues force de­lays

12 hours ago
Pharma

Covid-19 roundup: Pfiz­er/BioN­Tech sub­mit vac­cine da­ta to FDA for younger chil­dren; Doc­tors kept pre­scrib­ing ...

12 hours ago
Coronavirus

George Church, his stu­dents, and top VCs go na­tion­wide with a biotech train­ing camp

14 hours ago
Startups
see latest stream
People

Trevor Bed­ford, Cigall Kadoch among this year's in­com­ing HH­MI in­ves­ti­ga­tors

4 days ago

Fore­site re­cruits Prin­cip­ia vet Mar­tin Babler — and his old team — to oc­cu­py the C-suite of a start­up

5 days ago

The fire un­der Glax­o­SmithK­line's Em­ma Walm­s­ley grows as an­oth­er well-known ac­tivist in­vestor grabs its pitch­fork — ...

6 days ago
Financing

Look­ing to rewrite the rules of drug li­cens­ing, start­up An­ji is on the hunt for 'dy­nam­ic eq­ui­ty' joint ven­tures

16 hours ago

A new psy­che­delics play­er emerges to treat men­tal health dis­or­ders — mi­nus the hal­lu­cino­genic ef­fects

Yesterday

Look­ing to make donor cells ob­so­lete, an ex-Har­vard re­searcher gets off-the-shelf stem cell biotech off the ground

5 days ago
Startups

Eli Lil­ly gets be­hind the lat­est ap­proach to solv­ing gene ther­a­py's de­liv­ery prob­lem

5 days ago

Lux­tur­na in­ven­tor Jean Ben­nett starts a new gene ther­a­py com­pa­ny to tack­le rare dis­eases left be­hind by phar­ma, VCs

6 days ago

The End­points 11: They've got mad mon­ey and huge am­bi­tions. It's time to go big or go home

6 days ago
Deals

Bank­ing on in­te­grase in­hibitors as HIV cor­ner­stone, Vi­iV bags 3rd-gen­er­a­tion com­pound from Sh­iono­gi

15 hours ago

In­novent bets $250M+ on Union's PDE4 in­hibitor ahead of a PhII read­out

20 hours ago

Till­man Gern­gross project out of Dart­mouth Col­lege ac­quired by Repli­gen

5 days ago

Premium storiesSee all

The coro­n­avirus vac­cine that the world for­got could still help save it

Yesterday
Coronavirus
In Focus

FDA+ roundup: Bs­U­FA III ready for show­time, court tells FDA to re-work com­pound­ing plan, new guid­ance up­dates and ...

6 days ago
FDA+

So what hap­pened with No­var­tis Gene Ther­a­pies? Here's your an­swer

Last week
People
Bioregnum

Ex­clu­sives: Eli Lil­ly out to crash the megablock­buster PD-(L)1 par­ty with 'dis­rup­tive' pric­ing; re­veals can­cer ...

Last week
Bioregnum

Don't missSee all

Bio­gen can't es­cape co­pay kick­back law­suits as Hu­mana al­leges 'seed­ing and sweep­ing' scheme

Yesterday
Pharma

Bio­haven turns out a dud in fa­tal neu­rode­gen­er­a­tive dis­ease, cast­ing doubt on drug's chances in ALS

Yesterday
R&D

Mer­ck, Pfiz­er end patent feud over pneu­mo­coc­cal vac­cines with roy­al­ty-cen­tered set­tle­ment

Yesterday
Pharma

DE­VEL­OP­ING News: Ac­celeron ne­go­ti­at­ing $11B buy­out; 11 promis­ing biotech star­tups; Changes ga­lore at No­var­tis; ...

3 days ago
Weekly

Endpoints Standouts

Lega­cies: 60 bio­phar­ma pi­o­neers over 60 who helped birth a tech rev­o­lu­tion in the mak­ing

4 months ago
People
Special

The End­points 100 sur­vey: CEOs changed the way biotechs op­er­ate dur­ing the pan­dem­ic. Things will nev­er be the same ...

5 months ago
People
Special

The CHIC in­ter­view: Stéphane Ban­cel on Mod­er­na's overnight trans­for­ma­tion, the new time­line on vac­cine de­vel­op­ment ...

5 months ago
People
Publisher's note

The 20(+1) un­der 40: In­side the next gen­er­a­tion of biotech lead­ers

5 months ago
Special

Peer review See all

Sep
24

With Mav­er­ick now in Takeda's hands, James Sci­bet­ta turns the page; Roivant CMO leaves in fa­vor of small IL-2 biotech

Sep
17

A Pfiz­er part­ner wel­comes ex-ADC Ther­a­peu­tics CMO Jay Fein­gold to the team; Amid tough sled­ding, Im­muno­vant choos­es ...

Sep
10

Flag­ship keeps ex-FDA com­mish Stephen Hahn busy with an­oth­er CMO gig; Daphne Koller makes key hire at in­sitro by ...

Sep
3

Zio­pharm finds new CEO af­ter six-month search; CFO tran­si­tion at Lon­za to take place in De­cem­ber

Aug
27

As­traZeneca pro­motes on­col­o­gy ex­ec to CMO; Pfiz­er re­places re­tir­ing chief deal­mak­er as war chest ex­pands

Manufacturing channel feed

5 days ago

Lon­za un­veils new ex­pan­sion plans at Swiss man­u­fac­tur­ing sites, cap­ping off a very busy pan­dem­ic

Lon­za will ex­pand its drug de­vel­op­ment in Switzer­land yet again with in­vest­ments in three of its man­u­fac­tur­ing sites, the com­pa­ny an­nounced Wednes­day, cap­ping off a very busy year ...

READ MORE

Take­da breaks ground on ze­ro-emis­sion site in Asia; Boston Labs emerges from stealth with mo­bile cell, gene ther­a­py ...

5 days ago

Catal­ent inks deal with Phath­om to make GI drug at re­cent­ly-ren­o­vat­ed Ken­tucky site

5 days ago
Outsourcing
latest in Manufacturing

Re­call re­port: Pfiz­er pulls even more Chan­tix lots as ni­trosamine con­t­a­m­i­na­tion wor­ries grow

5 days ago

Covid-19 man­u­fac­tur­ing roundup: Bharat Biotech turns to oth­er pro­duc­ers to up sup­ply; Brazil, Ar­genti­na land mR­NA re­gion­al hubs

5 days ago
Coronavirus

Ver­ri­ca hits an­oth­er bump in the road with CMO re­lat­ed let­ter from FDA

Last week
FDA+

With plans to spend $360M, As­traZeneca will build its first-ever man­u­fac­tur­ing site in Ire­land

Last week

AGC un­veils Ger­man ex­pan­sion plans as gene and cell ther­a­py man­u­fac­tur­ing com­pe­ti­tion heats up

Last week
see latest stories

Pharma channel feed

Yesterday

Mer­ck touts a con­fir­ma­to­ry Keytru­da win for liv­er can­cer as 'dan­gling' ac­cel­er­at­ed ap­proval saga march­es on

Ac­cel­er­at­ed ap­proval for Mer­ck’s Keytru­da in a com­mon form of liv­er can­cer looked ten­u­ous af­ter a con­fir­ma­to­ry study whiffed on two sur­vival mea­sures. But af­ter ODAC rec­om­mend­ed to ...

READ MORE

No­vo Nordisk set­tles in­sulin pric­ing suit for $100M

Yesterday

HHS lines up No­var­tis, Lil­ly, As­traZeneca and 3 oth­er drug­mak­ers for fines due to drug dis­count vi­o­la­tions

5 days ago
latest in Pharma

Fol­low­ing con­tro­ver­sial Aduhelm ap­proval, DC-based neu­rol­o­gy cen­ter bans Bio­gen rep­re­sen­ta­tives from its of­fices — re­port

5 days ago
FDA+

Roche's Foun­da­tion Med­i­cine is get­ting a new 16-sto­ry home in Boston's Sea­port Dis­trict

5 days ago

Aerie fires CEO af­ter lead pro­gram flop, com­ments about pri­ma­ry end­points be­ing 'not re­quired'

Last week
People

Ex-My­lan em­ploy­ee pleads guilty to in­sid­er trad­ing, il­le­gal­ly deal­ing on FDA ap­provals, earn­ings and Up­john merg­er

Last week

Boston, the Bay Area and San Diego dom­i­nate the life sci­ences re­al es­tate mar­ket. Where to next?

Last week
see latest stories

R&D channel feed

15 hours ago

Sanofi calls it quits on mR­NA Covid-19 shots, scrap­ping vac­cine from $3.2B Trans­late Bio buy­out

Sanofi is throw­ing in the tow­el on mR­NA-based Covid-19 vac­cines.

READ MORE

On a jour­ney to dras­ti­cal­ly speed up cell ther­a­py man­u­fac­tur­ing, Ky­topen lands $30M Se­ries A

15 hours ago

Mi­cro­cap gene ther­a­py play­er says three chil­dren suf­fered se­ri­ous side ef­fects in PhI/II study

4 days ago
Cell/Gene Tx
latest in R&D

As­traZeneca and Mer­ck hope new da­ta can PRO­pel their PARP in­hibitor in­to first-line prostate can­cer

4 days ago

As­traZeneca teams up with Im­pe­r­i­al off­shoot Vax­E­quity on an RNA 3.0 ef­fort

5 days ago
Deals

With world still in sore need of dos­es, Clover says its Covid-19 vac­cine is 67% ef­fec­tive in Phase III

6 days ago
Coronavirus

Ex­elix­is pulls a sur­prise win in thy­roid can­cer just days ahead of fi­nal Cabome­tyx read­out

Last week
FDA+

As Bay­er, No­var­tis stack up their ra­dio­phar­ma­ceu­ti­cal da­ta at #ES­MO21, a key de­bate takes shape

Last week
In Focus
see latest stories

FDA+ channel feed

4 days ago

New ARIA cas­es dog Bio­gen's Aduhelm launch in an­oth­er po­ten­tial blow to block­buster hopes — an­a­lyst

Per­haps an­tic­i­pat­ing a walkover with an FDA ap­proval in hand, Bio­gen has in­stead faced a wall of push­back over its con­tro­ver­sial Alzheimer's med Aduhelm. With pay­ers and clin­ics ...

READ MORE

Tur­moil at CBER: Pe­ter Marks grabs con­trol of FDA's Of­fice of Vac­cines ahead of 2 key ca­reer leader de­par­tures

15 hours ago
Coronavirus

Seiz­ing Aduhelm prece­dent, Bio­gen, Ei­sai get the ball rolling on an­oth­er ac­cel­er­at­ed Alzheimer's ap­proval

Yesterday
latest in FDA+

Af­ter pump­ing the brakes on their An­gel­man syn­drome study, Ul­tragenyx and GeneTx are back in the race

Yesterday

UP­DAT­ED: CDC di­rec­tor over­rules ad­vi­sors on boost­ers, rec­om­mend­ing third shots for at-risk work­ers

4 days ago

FDA's can­cer drug ad­vi­sors will re­view 2 more dan­gling ac­cel­er­at­ed ap­provals for mul­ti­ple myelo­ma, leukemia

5 days ago

Mitch Mc­Connell, top Re­pub­li­cans ques­tion Biden on get­ting ahead of FDA on Covid-19 boost­ers

5 days ago
Coronavirus

In­cyte's rux­oli­tinib scores its sec­ond ap­proval in two days, this time in chron­ic graft-ver­sus-host dis­ease

5 days ago
see latest stories